Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“Combination of chemotherapy and omega 3 supplementation appears an effective strategy to enhance the clinical outcome of cancer (multiple myeloma) patients in their curative and palliative clinicalContinue reading
Patients with an acute medical illness such as pneumonia, stroke, or congestive heart failure are highly susceptible to the development of venous thromboembolism (VTE) during their hospital stay and upContinue reading
“The risk (cardiomyopathy) ranged from about 60% higher in ovarian cancer to over 300% higher in multiple myeloma.” Chemotherapy is toxic. Certain multiple myeloma chemotherapy regimens areContinue reading
The reduction in mortality was strongest for respiratory disease, neurodegenerative disease, and diabetes, followed by cancer (multiple myeloma!) and cardiovascular diseases. Mixed Nuts and Peanuts as multipleContinue reading
“An analysis of past studies shows 18 percent of multiple myeloma patients receiving carfilzomib experience cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks,Continue reading
“Given the frequency of cardiovascular risk factors in multiple myeloma patients as well as the cardiotoxicities associated with the different treatment regimens…” First do no harm? NotContinue reading
“These (CVD) complications can occur both acutely within the first 100 days as well as long-term, many years after the initial transplantation (HSCT) period…” I don’t know what’sContinue reading
“Given the frequency of cardiovascular risk factors in multiple myeloma patients as well as the cardiotoxicities associated with the different treatment regimens, it is essential to closely monitorContinue reading
Carfilzomib was associated with a significant incidence of cardiovascular adverse events (in multiple myeloma), with higher rates seen with higher doses of carfilzomib. When thinking about multiple myelomaContinue reading